ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The structure-based drug discovery start-up Charm Therapeutics has launched with $50 million in series A financing. Charm uses 3D deep learning to identify and develop small-molecule therapies for hard-to-drug targets in cancer and other conditions. The firm says its DragonFold algorithm predicts how ligands bind with protein targets implicated in disease. Charm is based on the work of cofounder David Baker, head of the Institute for Protein Design at the University of Washington.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X